FUNDACIO INSTITUT D'INVESTIGACIO SANITARIA ILLES BALEARS

Their core work

IdISBa is the health research institute of the Balearic Islands, conducting biomedical research with a strong focus on infectious disease, antimicrobial resistance, and immune-mediated conditions. Their work spans from fundamental immunology — studying autoimmunity, inflammation, and disease stratification — to applied nanotechnology solutions for targeted antibacterial treatment. They also contribute to AMR surveillance networks using next-generation sequencing and microbiome analysis, bridging clinical research with public health monitoring.

What they specialise in

How they've shifted over time

IdISBa's H2020 portfolio is compact (2019–2020 start dates) but shows a clear thematic arc. Their earliest involvement was in the large-scale 3TR consortium focused on autoimmunity, inflammation, and disease stratification using integrative genomics and predictive modeling. By 2020, their own-led work had shifted decisively toward antimicrobial resistance — both through nanotechnology-based therapeutics (REBELLION) and genomic surveillance networks (AmReSu), suggesting AMR became a strategic institutional priority.

IdISBa is consolidating around antimicrobial resistance as a core theme, combining nano-therapeutics with genomic surveillance — expect future proposals at the intersection of AMR, nanotechnology, and precision infection medicine.

How they like to work

IdISBa operates in mixed roles — coordinator, participant, and third party — across their three projects, showing flexibility rather than a fixed position in consortia. Their 90 unique partners across 17 countries indicate broad network reach, largely driven by the massive 3TR consortium. As a coordinator (REBELLION), they led a Widening-funded project, suggesting they are building independent project leadership capacity while maintaining connections within large European networks.

Despite only 3 projects, IdISBa has worked with 90 unique partners across 17 countries, primarily through the large 3TR consortium. This gives them a wide European contact base disproportionate to their project count.

What sets them apart

IdISBa brings together nano-therapeutics for infection and genomic AMR surveillance under one institutional roof — a combination rarely found in regional health research institutes. Based in the Balearic Islands, they are a Widening-eligible institution that has successfully coordinated EU funding, making them an attractive partner for consortia needing geographic diversity with genuine scientific contribution. Their dual capability in bench-side nanotechnology and computational genomics positions them to bridge experimental and data-driven approaches to infectious disease.

Highlights from their portfolio

• REBELLION
  Their only coordinated project, developing light-responsive nanomachines against bacterial pathogens — a distinctive and specific technological approach to AMR that defines their independent research identity.
• 3TR
  A large-scale (2019–2026) consortium on treatment non-response in autoimmune diseases, connecting IdISBa to a vast European network of 90+ partners as a third-party contributor.
• AmReSu
  A CSA focused on building AMR surveillance capacity through next-generation sequencing, aligning with EU public health priorities and complementing their therapeutic AMR work in REBELLION.